Akatinol Memantine, 5 mg+10 mg+15 mg+20 mg 7 pcs.

Pharmgroup:

A treatment for dementia

Pharm Action:

As a noncompetitive N-methyl-D-aspartate (NMDA)-receptor antagonist, it has modulatory effects on the glutamatergic system.

It regulates ion transport, blocks calcium channels, normalizes membrane potential, improves the process of nerve impulse transmission. Improves cognitive processes, increases daily activity.

Pharmacokinetics:

Akatinol Memantine is quickly and completely absorbed after oral administration. Maximum plasma concentration is reached within 2-6 hours. No cumulation of the drug is noted with normal renal function.

Extraction is biphasic. Period of semiejection half-life is 4-9 hours in the first phase and 40-65 hours in the second phase. It is excreted with urine.

Indications

Attention and memory disorders, Alzheimer’s disease, Acquired dementia

• Degenerative dementia (Alzheimer’s type), vascular dementia, mixed dementia of all degrees of severity. Alzheimer’s disease, Pick’s disease
• Dementia syndrome, depression in dementia
• Weakening of memory, ability to concentrate and learning ability
• Diseases that require increased vigilance, such as after craniocerebral trauma, open or closed brain injuries, comas, comas

Active ingredient

Memantine

Composition

1 coated tablet contains:

the active ingredient:

Memantine gilrochloride 5, 10, 15, 20 mg;

excipients:

lactose,

MCC,

colloidal silicon dioxide, <

Talc,

Magnesium stearate,

coating:

methacrylic acid copolymer, sodium lauryl sulfate, talc

How to take, the dosage

The dosing regimen is set on an individual basis.

It is recommended to start treatment with prescription of the minimum effective doses of Akatinol Memantine.

In adults with dementia syndrome it is prescribed for the 1st week of therapy in a dose of 5 mg per day, for the 2nd week – in a dose of 10 mg per day.

For the 3rd week, in a dose of 15-20 mg per day.

If necessary, further weekly dose increases by 10 mg until a daily dose of 30 mg is reached.

The optimal dose is reached gradually by increasing the dose each week.

Interaction

In concomitant use of Akatinol Memantine with drugs L-dopa, dopamine agonists, anticholinergic agents the effect of the latter may be enhanced.

In concomitant use with barbiturates, neuroleptics the effect of the latter may decrease.

When co-administration change (increase or decrease) the effect of dantrolene or baclofen, so the doses of the drugs should be adjusted individually.

Concomitant administration with amantadine, ketamine, and dexamethophan should be avoided.

Possible increase in plasma levels of cimetidine, procainamide, quinidine, quinine and nicotine when concomitantly administered with memantine.

Hydrochlorthiazide levels may decrease when taken concomitantly with memantine.

Special Instructions

For patients with impaired renal function, the dosing regimen is set individually, depending on clinical effectiveness, with monitoring of renal function during treatment.

Accatinol Memantine may change the effect of dantrolene or baclofen when used together, so doses should be adjusted individually.

In patients with moderate to severe dementia with Alzheimer’s disease, the ability to drive or operate machinery is usually impaired.

Contraindications

• individual hypersensitivity to the drug Akatinol Memantine;
• explicit renal dysfunction;
• pregnancy;
• breastfeeding;
• children under 18 years of age (due to insufficient data).

With caution:

• thyrotoxicosis;
• epilepsy;
• convulsions (including.
• myocardial infarction
• heart failure.

Side effects

Adverse reactions are classified according to clinical manifestations (according to the involvement of certain organ systems) and by frequency of occurrence:

In the body as a whole – general adverse reactions

Often Headache

Rarely Fatigue

Infections

Rarely Fungal infections

Mental disorders

Frequent Drowsiness

Rarely Confusion

Rarely Hallucinations

Frequency not determined

/p>

Psychotic reactions

Cardiovascular disorders

Rarely Hypertension

br>

Rarely Venous thrombosis/thromboembolism

Gastrointestinal disorders

Often Constipation

Rarely Nausea, Vomiting

Prevalence not established Pancreatitis

Disorders of the central and peripheral nervous system/p>

Frequent Dizziness

Rare Gait Disorder

Very rare Seizures

Hallucinations have been observed mainly in patients with Alzheimer’s disease at the stage of severe dementia.

There have been isolated reports of these adverse reactions when the drug is used in clinical practice (data obtained after the drug was commercially available).

.

Overdose

Symptoms: increased severity of side effects.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

.

Similarities

Noogeron, Maruksa, Memantal, Memaneirin, Memantine